Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2013. The report details a specific share repurchase transaction executed on August 1, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 294,600 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,712.00 pence per share; lowest price paid was 1,680.50 pence per share.
- Treasury Holdings (Settled): 505,049,512 shares (9.33% of total issued share capital).
- Treasury Holdings (Including Unsettled): 505,700,112 shares (10.31% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,907,117,925 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 294,600 shares for treasury. Consequently, the percentage of total voting rights held in treasury increased to 10.31% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (505,049,512 settled) against the company's latest capitalization table.
- Confirm the total issued share capital excluding treasury shares (4,907,117,925) for voting rights calculations.
- Check the price paid per share (1,680.50 to 1,712.00 pence) against market prices on August 1, 2013.
- Review the remaining authority for share buybacks under the mandate granted on May 1, 2013.